Cargando…
Correction: Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells
Autores principales: | Liu, Chun-Yu, Hu, Ming-Hung, Hsu, Chia-Jung, Huang, Chun-Teng, Wang, Duen-Shian, Tsai, Wen-Chun, Chen, Yi-Ting, Lee, Chia-Han, Chu, Pei-Yi, Hsu, Chia-Chi, Chen, Ming-Huang, Shiau, Chung-Wai, Tseng, Ling-Ming, Chen, Kuen-Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354698/ https://www.ncbi.nlm.nih.gov/pubmed/28222497 http://dx.doi.org/10.18632/oncotarget.15112 |
Ejemplares similares
-
Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2016) -
CIP2A is a target of bortezomib in human triple negative breast cancer cells
por: Tseng, Ling-Ming, et al.
Publicado: (2012) -
Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression
por: Liu, Chun-Yu, et al.
Publicado: (2019) -
Bortezomib Congeners Induce Apoptosis of Hepatocellular Carcinoma via CIP2A Inhibition
por: Hou, Duen-Ren, et al.
Publicado: (2013) -
Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A–dependent phospho-Akt inactivation in estrogen receptor–negative human breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2014)